A population-based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination

Cosette M. Wheeler, William C. Hunt, Jack Cuzick, Erika Langsfeld, Amanda Pearse, George D. Montoya, Michael Robertson, Catherine A. Shearman, Philip E. Castle

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Currently, two prophylactic human papillomavirus (HPV) vaccines targeting HPV 16 and 18 have been shown to be highly efficacious for preventing precursor lesions although the effectiveness of these vaccines in real-world clinical settings must still be determined. Toward this end, an ongoing statewide surveillance program was established in New Mexico to assess all aspects of cervical cancer preventive care. Given that the reduction in cervical cancer incidence is expected to take several decades to manifest, a systematic population-based measurement of HPV type-specific prevalence employing an age- and cytology-stratified sample of 47,617 women attending for cervical screening was conducted prior to widespread HPV vaccination. A well-validated polymerase chain reaction (PCR) method for 37 HPV genotypes was used to test liquid-based cytology specimens. The prevalence for any of the 37 HPV types was 27.3% overall with a maximum of 52% at age of 20 years followed by a rapid decline at older ages. The HPV 16 prevalences in women aged ≤20 years, 21-29 years or a;̂yen30 years were 9.6, 6.5 and 1.8%, respectively. The combined prevalences of HPV 16 and 18 in these age groups were 12.0, 8.3 and 2.4%, respectively. HPV 16 and/or HPV 18 were detected in 54.5% of high-grade squamous intraepithelial (cytologic) lesions (HSIL) and in 25.0% of those with low-grade SIL (LSIL). These baseline data enable estimates of maximum HPV vaccine impact across time and provide critical reference measurements important to assessing clinical benefits and potential harms of HPV vaccination including increases in nonvaccine HPV types (i.e., type replacement).

Original languageEnglish (US)
Pages (from-to)198-207
Number of pages10
JournalInternational Journal of Cancer
Volume132
Issue number1
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Vaccination
Human papillomavirus 16
Genotype
Human papillomavirus 18
Population
Papillomavirus Vaccines
Uterine Cervical Neoplasms
Cell Biology
Preventive Medicine
Vaccines
Age Groups
Polymerase Chain Reaction
Incidence

Keywords

  • HPV vaccine impact
  • population-based HPV prevalence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

A population-based study of human papillomavirus genotype prevalence in the United States : Baseline measures prior to mass human papillomavirus vaccination. / Wheeler, Cosette M.; Hunt, William C.; Cuzick, Jack; Langsfeld, Erika; Pearse, Amanda; Montoya, George D.; Robertson, Michael; Shearman, Catherine A.; Castle, Philip E.

In: International Journal of Cancer, Vol. 132, No. 1, 01.01.2013, p. 198-207.

Research output: Contribution to journalArticle

Wheeler, Cosette M. ; Hunt, William C. ; Cuzick, Jack ; Langsfeld, Erika ; Pearse, Amanda ; Montoya, George D. ; Robertson, Michael ; Shearman, Catherine A. ; Castle, Philip E. / A population-based study of human papillomavirus genotype prevalence in the United States : Baseline measures prior to mass human papillomavirus vaccination. In: International Journal of Cancer. 2013 ; Vol. 132, No. 1. pp. 198-207.
@article{ec6f7bd8920248b99c84c21601b78964,
title = "A population-based study of human papillomavirus genotype prevalence in the United States: Baseline measures prior to mass human papillomavirus vaccination",
abstract = "Currently, two prophylactic human papillomavirus (HPV) vaccines targeting HPV 16 and 18 have been shown to be highly efficacious for preventing precursor lesions although the effectiveness of these vaccines in real-world clinical settings must still be determined. Toward this end, an ongoing statewide surveillance program was established in New Mexico to assess all aspects of cervical cancer preventive care. Given that the reduction in cervical cancer incidence is expected to take several decades to manifest, a systematic population-based measurement of HPV type-specific prevalence employing an age- and cytology-stratified sample of 47,617 women attending for cervical screening was conducted prior to widespread HPV vaccination. A well-validated polymerase chain reaction (PCR) method for 37 HPV genotypes was used to test liquid-based cytology specimens. The prevalence for any of the 37 HPV types was 27.3{\%} overall with a maximum of 52{\%} at age of 20 years followed by a rapid decline at older ages. The HPV 16 prevalences in women aged ≤20 years, 21-29 years or a;̂yen30 years were 9.6, 6.5 and 1.8{\%}, respectively. The combined prevalences of HPV 16 and 18 in these age groups were 12.0, 8.3 and 2.4{\%}, respectively. HPV 16 and/or HPV 18 were detected in 54.5{\%} of high-grade squamous intraepithelial (cytologic) lesions (HSIL) and in 25.0{\%} of those with low-grade SIL (LSIL). These baseline data enable estimates of maximum HPV vaccine impact across time and provide critical reference measurements important to assessing clinical benefits and potential harms of HPV vaccination including increases in nonvaccine HPV types (i.e., type replacement).",
keywords = "HPV vaccine impact, population-based HPV prevalence",
author = "Wheeler, {Cosette M.} and Hunt, {William C.} and Jack Cuzick and Erika Langsfeld and Amanda Pearse and Montoya, {George D.} and Michael Robertson and Shearman, {Catherine A.} and Castle, {Philip E.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1002/ijc.27608",
language = "English (US)",
volume = "132",
pages = "198--207",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - A population-based study of human papillomavirus genotype prevalence in the United States

T2 - Baseline measures prior to mass human papillomavirus vaccination

AU - Wheeler, Cosette M.

AU - Hunt, William C.

AU - Cuzick, Jack

AU - Langsfeld, Erika

AU - Pearse, Amanda

AU - Montoya, George D.

AU - Robertson, Michael

AU - Shearman, Catherine A.

AU - Castle, Philip E.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Currently, two prophylactic human papillomavirus (HPV) vaccines targeting HPV 16 and 18 have been shown to be highly efficacious for preventing precursor lesions although the effectiveness of these vaccines in real-world clinical settings must still be determined. Toward this end, an ongoing statewide surveillance program was established in New Mexico to assess all aspects of cervical cancer preventive care. Given that the reduction in cervical cancer incidence is expected to take several decades to manifest, a systematic population-based measurement of HPV type-specific prevalence employing an age- and cytology-stratified sample of 47,617 women attending for cervical screening was conducted prior to widespread HPV vaccination. A well-validated polymerase chain reaction (PCR) method for 37 HPV genotypes was used to test liquid-based cytology specimens. The prevalence for any of the 37 HPV types was 27.3% overall with a maximum of 52% at age of 20 years followed by a rapid decline at older ages. The HPV 16 prevalences in women aged ≤20 years, 21-29 years or a;̂yen30 years were 9.6, 6.5 and 1.8%, respectively. The combined prevalences of HPV 16 and 18 in these age groups were 12.0, 8.3 and 2.4%, respectively. HPV 16 and/or HPV 18 were detected in 54.5% of high-grade squamous intraepithelial (cytologic) lesions (HSIL) and in 25.0% of those with low-grade SIL (LSIL). These baseline data enable estimates of maximum HPV vaccine impact across time and provide critical reference measurements important to assessing clinical benefits and potential harms of HPV vaccination including increases in nonvaccine HPV types (i.e., type replacement).

AB - Currently, two prophylactic human papillomavirus (HPV) vaccines targeting HPV 16 and 18 have been shown to be highly efficacious for preventing precursor lesions although the effectiveness of these vaccines in real-world clinical settings must still be determined. Toward this end, an ongoing statewide surveillance program was established in New Mexico to assess all aspects of cervical cancer preventive care. Given that the reduction in cervical cancer incidence is expected to take several decades to manifest, a systematic population-based measurement of HPV type-specific prevalence employing an age- and cytology-stratified sample of 47,617 women attending for cervical screening was conducted prior to widespread HPV vaccination. A well-validated polymerase chain reaction (PCR) method for 37 HPV genotypes was used to test liquid-based cytology specimens. The prevalence for any of the 37 HPV types was 27.3% overall with a maximum of 52% at age of 20 years followed by a rapid decline at older ages. The HPV 16 prevalences in women aged ≤20 years, 21-29 years or a;̂yen30 years were 9.6, 6.5 and 1.8%, respectively. The combined prevalences of HPV 16 and 18 in these age groups were 12.0, 8.3 and 2.4%, respectively. HPV 16 and/or HPV 18 were detected in 54.5% of high-grade squamous intraepithelial (cytologic) lesions (HSIL) and in 25.0% of those with low-grade SIL (LSIL). These baseline data enable estimates of maximum HPV vaccine impact across time and provide critical reference measurements important to assessing clinical benefits and potential harms of HPV vaccination including increases in nonvaccine HPV types (i.e., type replacement).

KW - HPV vaccine impact

KW - population-based HPV prevalence

UR - http://www.scopus.com/inward/record.url?scp=84868205558&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868205558&partnerID=8YFLogxK

U2 - 10.1002/ijc.27608

DO - 10.1002/ijc.27608

M3 - Article

C2 - 22532127

AN - SCOPUS:84868205558

VL - 132

SP - 198

EP - 207

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 1

ER -